RemeGen Co., Ltd. (HKG:9995, SHA:688331), a leading biopharmaceutical company, saw its shares surge nearly 8% on Tuesday after reporting robust revenue growth in the third quarter, despite posting a net loss for the period.
According to the company's financial results released on Tuesday, RemeGen reported a net loss attributable to shareholders of 291.0 million yuan ($41.1 million) for the quarter ended September 30. However, the company's revenue rose by an impressive 34.6% year-over-year to 467.1 million yuan ($66.0 million), indicating strong underlying business performance.
The positive revenue growth figures appeared to overshadow the net loss concerns, as investors bid up RemeGen's shares in both Hong Kong and Shanghai markets. The company's Hong Kong-listed shares gained 3% in morning trade on Wednesday, while its Shanghai-listed shares rose nearly 4%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。